AI halved OAR contouring time but serial organs still required careful review
AI reduced six-OAR contouring workflow from about 20 to 9.5 minutes, while spinal cord and brainstem differences remained clinically relevant.
Latest research
Search the archiveRectal retractors reduced rectal dose but increased bladder dose in cervical brachytherapy
Rectal retractor use lowered rectal D2cc and was associated with fewer grade ≥2 vaginal adverse events without reducing target coverage.
Most breast cancer RT appears safe with ADCs, but T-DM1 raises concern after brain SRS
Across 3,817 patients, severe toxicity was uncommon with RT plus ADCs, except for a radiation-necrosis signal with intracranial RT and T-DM1.
Five-fraction SBRT better preserves quality of life before pancreatic cancer surgery
In randomized phase II SOFT Preop, five-fraction SBRT better preserved patient-reported quality of life than 28-fraction chemoradiotherapy. Pathological nodal positivity did not differ significantly, but oncologic noninferiority was not established.
Paclitaxel-based trimodality therapy shows promising control but substantial toxicity in cutaneous angiosarcoma
In a small phase II study, induction and concurrent paclitaxel with RT, usually followed by surgery, achieved 82.5% two-year PFS in cutaneous angiosarcoma. Grade 3+ acute and late toxicity occurred in 58% and 32%, respectively.
Weekly cisplatin fails to reduce overall acute toxicity during head and neck chemoradiotherapy
NRG-HN009 found no reduction in overall acute grade 3-4 toxicity with weekly versus three-weekly cisplatin during definitive head and neck RT. Toxicity profiles differed, and neither phase II cohort met the criteria to proceed to phase III.
SBRT shows better 5-year patient-reported erectile function than prostatectomy in PACE-A
In PACE-A, moderate-to-severe erectile dysfunction at 5 years affected 44% of SBRT respondents vs 89% after prostatectomy. The patient-reported difference was significant, but analyses were as treated and follow-up questionnaires were incomplete.
PACIFIC-style CRT offers a curative fallback when resectable NSCLC becomes unresectable during neoadjuvant therapy
In MDT-BRIDGE, patients who became unresectable during neoadjuvant durvalumab plus chemotherapy could transition to definitive CRT and consolidation durvalumab, with 85% 12-month PFS in a small selected cohort.
Starting TTFields during chemoradiotherapy does not improve survival in newly diagnosed glioblastoma
TRIDENT found no OS benefit from starting TTFields during RT/TMZ rather than at maintenance in newly diagnosed glioblastoma. Median OS was 17.7 vs 17.5 months. A post hoc MGMT-methylated subgroup signal remains exploratory.
Ultrasound probe sparing preserved target coverage in photon cardiac radioablation plans
Photon STAR plans kept an echocardiographic probe below 1 Gy without compromising target coverage, although low-dose spread increased modestly.
Very late toxicities emerged more than a decade after stage I lung SBRT
Ten-year lung SBRT survivors developed rare airway, chest-wall and pericardial toxicities, while no local failures occurred beyond year 10.
Neoadjuvant ADT obscured 40% of MRI-visible prostate lesions before focal boost
After neoadjuvant ADT, 40% of MRI-visible prostate lesions disappeared and remaining lesions shrank substantially more than the prostate gland.
NRG-BN010 immuno-RT combination failed to improve response in recurrent glioblastoma
Tocilizumab, atezolizumab and 24 Gy/3-fraction FSRT produced only a 3.4% objective response rate in recurrent glioblastoma.
Previous pain response strongly predicted benefit from palliative reirradiation
Pain response after reirradiation was 60% in lesions that previously responded to RT versus 15% after primary nonresponse.
Breast skin V40 predicted lymphedema after breast-conserving therapy
Skin V40 >90 cc nearly quadrupled breast lymphedema odds, while mammographic skin thickening provided an objective detection signal.